natgillin/translations-raw huggingface dataset:
Ramucirumab therapy should be permanently discontinued in the event of:
Trajno prekinite zdravljenje z ramucirumabom v naslednjih primerih:
Randomisation was stratified by BRAF and tumour PD-L1 status and best response to prior ipilimumab.
Randomizacija je bila razslojena glede na status BRAF in status PD-L1 tumorja ter najboljši odziv na predhodno zdravljenje z ipilimumabom.
Randomisation was stratified by breast cancer type (operable, locally advanced, or inflammatory) and ER and /or PgR positivity.
Randomizacija je bila stratificirana glede na tip raka dojk (operabilen, lokalno napredovali ali vnetni) in glede na pozitivnost ER in PgR.
Randomisation was stratified by breast cancer type (operable, locally advanced, or inflammatory) and ER or PgR positivity.
Randomizacija je bila stratificirana glede na tip raka dojk (operabilen, lokalno napredovali ali vnetni) in glede na pozitivnost ER in PgR.
Randomisation was stratified by geographic region (Europe, North America, and Other), prior VEGF/VEGFR-targeted therapy (patients may have received 0 or 1 prior VEGF/VEGFR-targeted therapy), and age (≤65 years or >65 years).
Randomizacija je bila stratificirana po zemljepisnih regijah (Evropa, Severna Amerika, drugo), predhodnem zdravljenju, usmerjenem v VEGF/VEGFR (bolniki so lahko prejeli 0 ali 1 predhodno zdravljenje, usmerjeno v VEGF/VEGFR), in starosti (≤65 let ali >65 let).
Randomisation was stratified by geographic region, gender, prior maintenance, and ECOG PS.
Randomizacija je bila stratificirana po geografski regiji, spolu, predhodnem vzdrževanju stanja in indeksu stanja zmogljivosti ECOG.
Randomisation was stratified by PD-L1 expression (≥5% vs. <5% tumour cell membrane expression), BRAF status, and M stage per the American Joint Committee on Cancer (AJCC) staging system.
Randomizacija je bila razslojena glede na ekspresijo PD-L1 (≥ 5 % v primerjavi z < 5 % ekspresije celične membrane tumorja), status BRAF in M stadij po kriterijih Ameriškega združenja za zdravljenje raka (AJCC - American Joint Committee on Cancer).
Randomisation was stratified by screening HIV-1 RNA level (≤ 100,000 copies/mL or
Randomizacija je bila stratificirana s presejanjem ravni HIV-1 RNA
Randomisation was stratified by tumour PD-L1 status and M stage (M0/M1a/M1b versus M1c).
Randomizacija je bila razslojena glede na status PD-L1 tumorja in M stadij (M0/M1a/M1b v primerjavi z M1c).
Randomisation was stratified by use of tenofovir disoproxil fumarate and/or lopinavir/ritonavir in the baseline regimen.
Randomizacija je bila stratificirana z uporabo dizoproksiltenofovirijevega fumarata in/ali lopinavirja/ritonavirja v začetnem režimu.
Randomised
Randomizirano
Randomised Efficacy Sample a, b
LOCF: randomizirani vzorec učinkovitosti a, b
Randomised Levemir + liraglutide + metformin N = 160
Randomizirani na zdravilo Levemir + liraglutid + metformin n = 160
Randomised patients received either “low dose” UFH regimen (50 U/kg irrespective of planned GPIIb/IIIa use; non ACT guided) or “standard dose” UFH regimen (no GPIIb/IIIa use: 85 U/kg, ACT guided; planned GPIIb/IIIa use: 60 U/kg, ACT guided) immediately prior to the start of the PCI.
Randomizirani bolniki so prejemali bodisi shemo z "nizkim odmerkom" UFH (50 e./kg ne glede na načrtovano uporabo GPIIb/IIIa; ne po ACT) bodisi shemo s "standardnim odmerkom" UFH (brez uporabe GPIIb/IIIa: 85 e./kg, po ACT; načrtovana uporaba GPIIb/IIIa: 60 e./kg, po ACT) tik pred začetkom PCI.
Randomised patients stage III optimally debulked disease 2,3
Randomizirane bolnice z optimalno citoredukcijo, stadija III 2,3
Randomised patients stage III optimally debulked disease 2,3
Randomizirane bolnice z optimalno citoredukcijo, stadija III2,3
Randomised patients with stage III suboptimally debulked disease3
Randomizirane bolnice s suboptimalno citoredukcijo, stadija III3
Randomised phase 3 study of nivolumab in combination with ipilimumab or nivolumab as monotherapy vs. ipilimumab as monotherapy (CA209067)
Randomizirana študija 3. faze uporabe nivolumaba v kombinaciji z ipilimumabom ali nivolumaba v monoterapiji v primerjavi z ipilimumabom v monoterapiji (študija CA209067)
Randomised phase 3 study vs. chemotherapy (CA209037)
Randomizirana študija 3. faze v primerjavi s kemoterapijo (študija CA209037)
Randomised phase 3 study vs. dacarbazine (CA209066)
Randomizirana študija 3. faze v primerjavi z dakarbazinom (študija CA209066)
Randomised phase 3 study vs. docetaxel (CA209017)
Randomizirana študija 3. faze v primerjavi z docetakselom (študija CA209017)
Randomised phase 3 study vs. docetaxel (CA209057)
Randomizirana študija 3. faze v primerjavi z docetakselom (CA209057)
Randomised Treatment†
Randomizirano zdravljenje
Randomised, double-blind treatment regimen week 18 to 34
randomiziran, dvojno slep režim zdravljenja od 18. do 34. tedna
Randomization of patients was stratified by Sokal score and geographic region.
Randomizacija bolnikov je bila stratificirana na podlagi ocene po Sokalu in geografske regije.
Randomization to 12 months
Randomizacija do 12 mesecev
Randomization to 18 months
Randomizacija do 24 mesecev
Randomization to 24 months
Randomizacija do 18 mesecev
Randomization to 30 months
Randomizacija do 30 mesecev
Randomization to 36 months
Randomizacija do 36 mesecev
Randomization was stratified by screening HIV RNA level (≤50,000 copies/ml; and > 50,000 copies/ml) and by hepatitis B or C status (positive or negative).
Stratifikacija randomiziranih bolnikov je bila izvedena na osnovi vrednosti HIV RNA (≤ 50.000 kopij/ml in > 50.000 kopij/ml) in hepatitis B ali C statusa (pozitiven ali negativen).
Randomized and treated patients
Randomizirani in zdravljeni bolniki
Randomized and treated patients with baseline and at least 1 post-baseline efficacy measurement.
Randomizirani in zdravljeni bolniki z izhodiščno in vsaj še eno poizhodiščno meritvijo učinkovitosti.
Randomized controlled trial
Randomizirano kontrolirano preskušanje
Ranexa 375 mg prolonged-release tablets
Ranexa 375 mg tablete s podaljšanim sproščanjem
Ranexa 375 mg prolonged-release tablets Ranolazine
Ranexa 375 mg tablete s podaljšanim sproščanjem ranolazin
Ranexa 500 mg prolonged-release tablets
Ranexa 500 mg tablete s podaljšanim sproščanjem
Ranexa 500 mg prolonged-release tablets Ranolazine
Ranexa 500 mg tablete s podaljšanim sproščanjem ranolazin
Ranexa 750 mg prolonged-release tablets
Ranexa 750 mg tablete s podaljšanim sproščanjem
Ranexa 750 mg prolonged-release tablets Ranolazine
Ranexa 750 mg tablete s podaljšanim sproščanjem ranolazin
Ranexa can be taken with or without food.
Zdravilo Ranexa se lahko jemlje s hrano ali brez nje.
Ranexa is available as 375 mg, 500 mg, and 750 mg prolonged-release tablets.
Zdravilo Ranexa je na voljo v obliki 375-miligramskih, 500-miligramskih in 750-miligramskih tablet s podaljšanim sproščanjem.
Ranexa is contraindicated in patients taking:
Zdravilo Ranexa je kontraindicirano pri bolnikih, ki jemljejo:
Ranexa is contraindicated in patients with severe renal impairment (creatinine clearance  30 ml/min) (see sections 4.3 and 5.2).
Uporaba zdravila Ranexa je kontraindicirana pri bolnikih s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) (glejte poglavji 4.3 in 5.2).
Ranexa is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
Zdravilo Ranexa je indicirano kot dodatno zdravljenje za simptomatsko zdravljenje odraslih bolnikov s stabilno angino pektoris, pri katerih bolezen ni ustrezno nadzorovana ali ki ne prenašajo prve izbire zdravljenja proti angini (kot so beta-blokatorji ali antagonisti kalcija).
Ranexa may cause dizziness, blurred vision, diplopia, confusional state, coordination abnormal, hallucination (see section 4.8), which may affect the ability to drive and use machines.
Zdravilo Ranexa lahko povzroči omotico, zamegljen vid, diplopija, stanje zmedenosti, motnje v koordinaciji in halucinacije (glejte poglavje 4.8), kar lahko vpliva na sposobnost vožnje in upravljanja s stroji.
Ranexa may cause side effects such as dizziness (common), blurred vision (uncommon), confusional state (uncommon), hallucination (uncommon), double vision (uncommon), coordination problems (rare), that may affect your ability to drive or use machines.
Zdravilo Ranexa lahko povzroči neželene učinke, kot sta omotica (pogosto), zamegljen vid (občasno), stanje zmedenosti (občasno), halucinacije (občasno), dvojni vid (občasno), težave v koordinaciji (redko), ki lahko vplivajo na sposobnost vožnje in upravljanja strojev.
Ranexa Patient Alert Card (Information for Health Care Professionals)
Ranexa Kartica z opozorili za bolnika (Informacije za zdravnike)
Ranexa should not be used in patients treated with CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine, St. John’s Wort) (see section 4.5).
Zdravila Ranexa se ne sme uporabljati pri bolnikih, ki jemljejo spodbujevalce encima CYP3A4 (npr. rifampicin, fenitoin, fenobarbital, karbamazepin, šentjanževko) (glejte poglavje 4.5).
Ranexa with food and drink
Zdravilo Ranexa skupaj s hrano, pijačo in alkoholom
Range (µg/ml)
Razpon (µg/ml)
Range (µg/ml)
Razpon(µg/ml)
Ranibizumab 0.5 mg (n=131)
ranibizumab 0,5 mg (n=131)
Ranibizumab 0.5 mg Group I by stabilisation (n=105)
meseci ranibizumab 0,5 mg, skupina I režim glede na stabilnost (n=105)
Ranibizumab 0.5 mg/Verteporfin PDT Group III from Month 3 onwards (n=55)
režim glede na aktivnost bolezni (n=116) ranibizumab 0,5 mg/PDT z verteporfinom, skupina III od 3. meseca dalje (n=55)
Ranibizumab allowed
dovoljena uporaba ranibizumaba
Ranibizumab has been designed to block a substance called vascular endothelial growth factor A (VEGF-A).
Ranibizumab je zasnovan tako, da zavira snov, imenovano vaskularni endotelijski rastni dejavnik A (VEGF-A).
Ranitidine
felodipin, nifedipin,
Ranitidine
zdravili
Ranitidine: Ranitidine administration together with Pradaxa had no clinically relevant effect on the extent of absorption of dabigatran.
Ranitidin: Sočasno dajanje ranitidina in zdravila Pradaxa ni klinično pomembno vplivalo na obseg absorpcije dabigatrana.
Ranitidine: ↔
Lopinavir: ↔
Ranitidine: ↔
sakvinavir: ↔
ranolazine is contraindicated (see
ranolazinom je kontraindicirana
Rapamune 0.5 mg is supplied to you as tan-coloured, triangular-shaped coated tablets marked “RAPAMUNE 0.5 mg” on one side.
Zdravilo Rapamune 0,5 mg je v obliki rumenorjavih trikotnih obloženih tablet, ki so na eni strani označene z "RAPAMUNE 0,5 mg".
Rapamune 1 mg is supplied to you as white-coloured, triangular-shaped coated tablets marked “RAPAMUNE 1 mg” on one side.
Zdravilo Rapamune 1 mg je v obliki belih trikotnih obloženih tablet, ki so na eni strani označene z "RAPAMUNE 1 mg".
Rapamune 1 mg/mL oral solution
Rapamune 1 mg/ml peroralna raztopina
Rapamune 1 mg/mL oral solution Sirolimus
Rapamune 1 mg/ml peroralna raztopina sirolimus
Rapamune 2 mg is supplied to you as yellow to beige-coloured, triangular-shaped coated tablets marked “RAPAMUNE 2 mg” on one side.
Zdravilo Rapamune 2 mg je v obliki rumenih do bež trikotnih obloženih tablet, ki so na eni strani označene z "RAPAMUNE 2 mg".
Rapamune contains the active substance sirolimus, which belongs to a group of medicines called immunosuppressants.
Zdravilo Rapamune vsebuje zdravilno učinkovino sirolimus, ki sodi med zdravila za zaviranje imunske odzivnosti.
Rapamune contains up to 2.5 vol % ethanol (alcohol).
Zdravilo Rapamune vsebuje do 2,5 volumskih % etanola (alkohola).
Rapamune has been studied in two main studies involving a total of 1,295 patients who were having a kidney transplant and were at low to moderate risk of rejection.
Zdravilo Rapamune so proučili v dveh glavnih študijah, v kateri je bilo vključenih 1 295 bolnikov, ki so jim presadili ledvico in pri katerih je bilo tveganje zavrnitve nizko do zmerno.
Rapamune has no known influence on the ability to drive and use machines.
Zdravilo Rapamune nima znanega vpliva na sposobnost vožnje in upravljanja s stroji.
Rapamune has not been adequately studied in patients at high immunological risk, therefore use is not recommended in this group of patients (see section 5.1).
Pri bolnikih z visokim imunskim tveganjem zdravila Rapamune niso zadostno proučili, zato uporaba pri tej skupini bolnikov ni priporočljiva (glejte poglavje 5.1).
Rapamune is a medicine that contains the active substance sirolimus.
Rapamune je zdravilo, ki vsebuje zdravilno učinkovino sirolimus.
Rapamune is for oral use only.
Zdravilo Rapamune se uporablja samo peroralno.
Rapamune is used to prevent the body from rejecting a newly transplanted kidney.
Zdravilo Rapamune se uporablja za preprečevanje zavrnitve ledvice po presaditvi.
Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued (see sections 4.2 and 5.1).
Zdravljenje z zdravilom Rapamune se lahko nadaljuje kot vzdrževalno zdravljenje skupaj s kortikosteroidi le pri bolnikih, pri katerih se lahko mikroemulzija ciklosporina postopoma ukine (glejte tudi poglavji 4.2 in 5.1).
Rapamune must not be diluted in grapefruit juice or any other liquid other than water or orange juice (see section 6.6).
Zdravila Rapamune ne smemo redčiti s sokom grenivke niti s katero drugo tekočino, razen z vodo ali s pomarančnim sokom (glejte poglavje 6.6).
Rapamune oral solution contains polysorbate-80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC).
Zdravilo Rapamune peroralna raztopina vsebuje polisorbat 80, ki poveča izločanje di-(2- etilheksil)ftalata (DEHP) iz polivinil klorida (PVC).
Rapamune oral solution contains up to 2.5 vol % ethanol (alcohol).
Peroralna raztopina zdravila Rapamune vsebuje do 2,5 volumskih % etanola (alkohola).
Rapamune oral solution is a pale yellow to yellow solution supplied in a 60 mL bottle.
Peroralna raztopina zdravila Rapamune je bledorumena do rumena raztopina, ki je na voljo v 60- mililitrski steklenici.
Rapamune reduces your body’s own defence mechanisms to stop rejecting your transplanted organ.
Zdravilo Rapamune oslabi lastne obrambne mehanizme vašega telesa, da bi vam preprečilo, da bi zavrnili svoj presajeni organ.
Rapamune reduces your body’s own defence mechanisms to stop you rejecting your transplanted organ.
Zdravilo Rapamune oslabi lastne obrambne mehanizme vašega telesa, da bi vam preprečilo, da bi zavrnili svoj presajeni organ.
Rapamune should be given with corticosteroids.
Zdravilo Rapamune je treba kombinirati s kortikosteroidi.
Rapamune should be taken consistently, either with or without food.
Zdravilo Rapamune jemljite vedno enako, bodisi s hrano ali brez nje.
Rapamune should be taken consistently, either with or without food.
Zdravilo Rapamune vedno jemljite enako, bodisi s hrano ali brez nje.
Rapamune should be taken four hours after each ciclosporin dose.
Bolnik mora zdravilo Rapamune vzeti štiri ure po vsakem odmerku ciklosporina.
Rapamune should not be taken with grapefruit juice.
Ne jemljite zdravila Rapamune skupaj s sokom grenivke.
Rapamune should not be used during pregnancy unless clearly necessary.
Zdravila Rapamune ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Rapamune should not be used during pregnancy unless clearly necessary.
Zdravilo Rapamune naj se med nosečnostjo ne uporablja, če to ni nujno potrebno.
Rapamune tablets administered to 12 renal transplant patients above 65 years of age gave similar results to adult patients (n=167) 18 to 65 years of age.
Zdravilo Rapamune v tabletah, ki so ga dajali 12 bolnikom s presajeno ledvico, starejšim od 65 let, je dalo podobne rezultate kot pri odraslih bolnikih (n = 167), starih 18 do 65 let.
Rapamune therapy should be optimised with a tapering regimen of steroids and ciclosporin microemulsion.
Optimalno zdravljenje z zdravilom Rapamune se doseže s postopnim zmanjševanjem odmerka kortikosteroidov in mikroemulzije ciklosporina.
Rapamune treatment should be started by and remain under the guidance of a doctor who is a qualified specialist in transplantation.
Zdravljenje z zdravilom Rapamune sme uvesti in kasneje nadzorovati le usposobljen specialist za presaditve.
Rapamune was assessed in a 36-month controlled clinical study enrolling renal transplant patients below 18 years of age considered at high-immunologic risk, defined as having a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy.
Zdravilo Rapamune so ocenjevali v 36-mesečni kontrolirani klinični študiji, v katero so bili vključeni bolniki, mlajši od 18 let, po presaditvi ledvic, z velikim imunološkim tveganjem, kar pomeni z anamnezo ene ali več akutnih epizod zavrnitve alografta in/ali prisotnost kronične nefropatije alografta ob ledvični biopsiji.
Rapamune was more effective than placebo or azathioprine, when they were added to ciclosporin and corticosteroids.
Dodajanje zdravila Rapamune ciklosporinu in kortikosteroidom je bilo učinkovitejše od dodajanja placeba ali azatioprina.
Rapamycin
področjih (odmerek
Rapamycin Tacrolimus
ciklosporin rapamicin takrolimus
Rapamycin:  expected Tacrolimus:  expected
ciklosporin:  pričakovano rapamicin:  pričakovano takrolimus:  pričakovano
Rapid
EU/1/97/030/122
rapid and excessive weight gain
hitro in prekomerno povečanje telesne mase
rapid and excessive weight gain caused by fluid retention
hitro in močno povečanje telesne mase zaradi kopičenja tekočine v telesu
rapid and excessive weight gain caused by fluid retention increase of lactic acid in the blood.
hitro in močno povečanje telesne mase zaradi kopičenja tekočine v telesu. zvišanje vrednosti mlečne kisline v krvi.
rapid beating of the heart
hitro bitje srca
Rapid beating of the heart, tightness of the chest
hiter srčni utrip, tiščanje v prsih,
Rapid breakdown of muscles
hitra razgradnja mišic
Rapid breathing
hitro dihanje
rapid breathing
hitro dihanje. občutek hladu.
rapid breathing feeling cold or uncomfortable.
hitro dihanje občutek mraza ali neprijeten občutek
rapid correction of hyponatraemia, sometimes leading to neurological symptoms
hiter popravek hiponatriemije, ki včasih povzroči nevrološke simptome
rapid heart beat
hitro bitje srca,
Rapid heart beat (tachycardia)
pospešen krvni utrip (tahikardija)
rapid heart beat, agitation/aggressiveness, problems with speech. unusual movements (especially of the face or tongue) and reduced level of consciousness.
hitro bitje srca, vznemirjenost/agresivnost, težave pri govoru; nenavadne gibe (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Rapid heart beat, irregular heart beat, bluish skin
hiter srčni utrip, nereden srčni utrip, modrikasta koža
rapid heart rate
hiter srčni utrip,
rapid heart rate (tachycardia)
hitro bitje srca (tahikardija),
rapid heartbeat
hiter srčni utrip
Rapid heartbeat
hitro bitje srca
rapid heartbeat
hraður hjartsláttur
Rapid immunisation schedule (adults)
Urnik hitre imunizacije (odrasli)
rapid increase in your weight swollen ankles or feet.
hitro povečanje telesne mase. oteklino gležnjev ali nog.
rapid increase in your weight swollen ankles or feet.
oteklino gležnjev ali nog.
rapid irregular heart beat
hitro neredno bitje srca,
Rapid onset of bowel movement
Hiter začetek odvajanja blata
Rapid or abnormal heart beat
hiter ali nenormalen srčni utrip
rapid or irregular heartbeat
hitro ali nepravilno bitje srca
rapid or irregular heartbeat
hitro ali neredno bitje srca
rapid or irregular heartbeat;
hiter ali nepravilen srčni utrip;
rapid or irregular heartbeat;
hitro ali neredno bitje srca;
rapid or irregular heartbeats
hitro ali neredno bitje srca.
Rapid or weak pulse,
hiter ali slaboten pulz,
Rapid or weak pulse;
hiter ali šibek utrip
Rapid rebound reactions such as intensified pulmonary vasoconstriction and hypoxia after sudden withdrawal of inhaled nitric oxide therapy has been described, precipitating cardiovascular collapse.
Po nenadni prekinitvi zdravljenja z vdihavanjem dušikovega oksida so opisali hitre povratne (»rebound«) reakcije kot sta povečana pljučna vazokonstrikcija in hipoksija, ki so povzročile kardiovaskularni kolaps.
rapid rise in level of sodium
hitro zvišanje ravni natrija
Rapid schedule
Hitri urnik
Rapid Schedule (N)
Hitri urnik (N)
Rapid uncontrollable movement of the eyes (nystagmus)
hitri nekontrolirani gibi očesa (nistagmus)
rapid weight gain, swelling of hands, ankles, feet or face (signs of water retention)
hitro pridobivanje telesne teže, otekanje rok, gležnjev, stopal ali obraza (znaki zadrževanja vode v telesu)
rapid weight loss
hitra izguba telesne mase,
Rapid weight loss at a rate of > 1.5 kg per week has been reported in patients treated with exenatide.
Pri bolnikih, ki so se zdravili z eksenatidom, so poročali o hitri izgubi telesne mase, večji kot 1,5 kg tedensko.
Rapidly alternating muscular contraction and relaxation (clonus).
hitro in izmenično krčenje ter sprostitev mišic (klonus)
Rapilysin 10 U powder and solvent for solution for injection
Rapilysin 10 enot prašek in vehikel za raztopino za injiciranje
Rapilysin 10 U powder and solvent for solution for injection reteplase
Rapilysin 10 enot prašek in vehikel za raztopino za injiciranje reteplaza
Rapilysin 10 U powder and solvent for solution for injection Reteplase Intravenous use
Rapilysin 10 enot prašek in vehikel za raztopino za injiciranje reteplaza za intravensko uporabo
Rapilysin 10 U powder and solvent for solution for injection.
Rapilysin 10 enot prašek in vehikel za raztopino za injiciranje
Rapilysin contains the active substance reteplase(a recombinant plasminogen activator).
Zdravilo Rapilysin vsebuje zdravilno učinkovino reteplazo (rekombinantni aktivator plazminogena).
Rapilysin should be injected preferably through an intravenous line whose sole purpose is the injection of Rapilysin.
Zdravilo Rapilysin je najbolje injicirati skozi intravenski kanal, ki se uporablja samo za injiciranje zdravila Rapilysin.
Rapiscan 400 microgram solution for injection regadenoson
Rapiscan 400 mikrogramov raztopina za injiciranje regadenozon
Rapiscan administration may result in adverse reactions such as dizziness, headache, and dyspnoea (see section 4.8) soon after administration.
Dajanje zdravila Rapiscan lahko kmalu po dajanju povzroči neželene učinke kot so omotica, glavobol in dispneja (glejte poglavje 4.8).
Rapiscan can cause transient ischaemic attack (see section 4.8).
Zdravilo Rapiscan lahko povzroči prehodni ishemični napad (glejte poglavje 4.8).
Rapiscan contains the active substance regadenoson.
Zdravilo Rapiscan vsebuje zdravilno učinkovino imenovano regadenozon.
Rapiscan has the potential to cause serious and life-threatening reactions, including those listed below (see also section 4.8).
Zdravilo Rapiscan lahko povzroči resne ali življenjsko nevarne učinke, vključno s spodaj naštetimi (glejte tudi poglavje 4.8).
Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Rapiscan je selektivni koronarni vazodilatator, ki se uporablja kot zdravilo za farmakološko obremenitev pri radionuklidnem slikanju miokardne perfuzije pri odraslih bolnikih, ki niso zmožni obremenitve z vadbo.
Rapiscan is administered by intravenous injection.
Zdravilo Rapiscan se daje v obliki intravenskega injiciranja.
Rapiscan is used as a ‘stress agent’ that has a similar effect on the heart as exercise.
Zdravilo Rapiscan se uporablja kot „sredstvo za obremenitev“, ki ima podoben učinek na srce kot telesna vadba.
Rapiscan is used in a type of heart scan in adults called ‘myocardial perfusion imaging’.
Zdravilo Rapiscan se uporablja pri odraslih za določeno vrsto slikanja srca, ki se imenuje "perfuzijska scintigrafija miokarda".
Rapiscan may cause clinically significant increases in blood pressure, which in some patients can lead to hypertensive crisis (see section 4.8).
Zdravilo Rapiscan lahko povzroči klinično pomembna zvišanja krvnega tlaka, ki lahko pri nekaterih bolnikih pripeljejo do hipertenzivne krize (glejte poglavje 4.8).